Compare PRGS & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGS | FTRE |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1995 | 2023 |
| Metric | PRGS | FTRE |
|---|---|---|
| Price | $31.48 | $16.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $49.50 | $14.06 |
| AVG Volume (30 Days) | 567.2K | ★ 1.1M |
| Earning Date | 03-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | $397,572,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $3.70 | N/A |
| Revenue Next Year | $1.08 | $3.09 |
| P/E Ratio | $59.60 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $23.82 | $4.46 |
| 52 Week High | $65.50 | $18.67 |
| Indicator | PRGS | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 63.11 |
| Support Level | $26.18 | $15.66 |
| Resistance Level | $32.23 | $18.08 |
| Average True Range (ATR) | 1.41 | 1.09 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 37.64 | 78.80 |
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.